广泛期小细胞肺癌化免疫治疗后巩固性胸部放疗:一项多中心回顾性分析
这项多中心回顾性研究分析了2020年1月至2024年1月间4个中心接受一线化免疫治疗的广泛期小细胞肺癌患者,纳入首次治疗后评估无影像学进展者,比较接受与未接受巩固性胸部放疗患者的胸腔内复发率、无进展生存期和总生存期。336例患者中111例(33.0%)接受胸部放疗,放疗组胸腔内进展率低于未放疗组(40.5% vs 57.8%,p=0.003),但无进展生存期(HR 0.89,p=0.363)和总生存期(HR 0.82,p=0.142)改善未达统计学显著。
要点
- 放疗组胸腔内进展率40.5% vs 未放疗组57.8%(p=0.003)。
- 放疗组无进展生存期HR 0.89(p=0.363),总生存期HR 0.82(p=0.142),均未达统计学显著。
- 基线肝转移和化免疫治疗后稳定疾病是无进展生存期缩短的独立预测因素。
核心结论
- 在本系列中,一线化免疫治疗后胸部放疗显著改善了胸腔内控制,但未转化为显著更优的生存结局。
- 需要前瞻性试验评估胸部放疗对生活质量和生存的影响。
研究设计与样本
- 回顾性研究,分析2020年1月至2024年1月间4个中心连续接受一线化免疫治疗的广泛期小细胞肺癌患者。
- 纳入首次治疗后评估无影像学进展的患者,比较接受与未接受巩固性胸部放疗患者的胸腔内复发率、无进展生存期和总生存期。
- 共识别336例患者,其中111例(33.0%)接受胸部放疗。
主要发现
- 接受胸部放疗的患者胸腔内进展率低于未接受胸部放疗者(40.5% vs 57.8%,p=0.003)。
- 尽管接受胸部放疗,发生胸腔内进展的患者中仅21例(24.1%)在放疗野内进展。
- 中位随访31.3个月,接受胸部放疗的患者无进展生存期(HR 0.89,p=0.363)和总生存期(HR 0.82,p=0.142)改善,但未达统计学显著。
- 多因素分析确定基线肝转移和化免疫治疗后稳定疾病为无进展生存期缩短的独立预测因素。
- 亚组分析显示,接受较高胸部放疗剂量(≥45 Gy vs <45 Gy)和无肝转移的患者无进展生存期更长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CREST trial established the benefit of consolidative thoracic radiotherapy (TRT) following first line (1L) chemotherapy in extensive-stage small cell lung cancer (ES-SCLC), demonstrating improved 2-year overall survival (OS). However, the role of TRT in the chemoimmunotherapy (CT-IO) era remains unclear, as TRT was excluded from registrational trials. METHODS: This retrospective study analysed consecutive patients (pts) with ES-SCLC treated with 1L CT-IO between January 2020 and January 2024 across 4 centres. Pts without radiological progression (PD) at their first post-treatment assessment were included. Intrathoracic recurrence rates, progression-free survival (PFS), and OS were compared between pts who received TRT and those who did not. RESULTS: 336 pts were identified, with 111 (33.0 %) receiving TRT. Pts who received TRT had a lower rate of intrathoracic PD compared to those who did not (40.5 % vs 57.8 %, p = 0.003). Among those with intrathoracic PD despite TRT, only 21 (24.1 %) experienced PD within the radiation field. With a median follow-up of 31.3 months, pts who received TRT showed improved PFS (HR 0.89, p = 0.363) and OS (HR 0.82, p = 0.142), although not statistically significant. Multivariate analysis identified baseline liver metastases (LM) and stable disease after CT-IO as independent predictors of shorter PFS. Subgroup analysis revealed a longer PFS for pts receiving higher TRT doses (≥45 Gy vs <45 Gy) and those without LM. CONCLUSIONS: In this series, TRT following 1 L CT-IO significantly improved intrathoracic control, although it did not translate into significantly better survival outcomes. Prospective trials are warranted to evaluate the impact of TRT on quality of life and survival.
引用
- Monaca F, Gomez-Randulfe I, Walls G, et al. Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis. Eur J Cancer. 2025. PMID: 40580810. doi:10.1016/j.ejca.2025.115592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。